Skip to main navigation This site uses cookies as described in our Privacy Notice. Please click Accept if you agree to the use of cookies on our site. Accept INVESTORS G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. Stock Quote Price $13.66 Change 0 (0.00%) Volume 470,240 NASDAQ GS: GTHX Nov 24, 2021 4:00 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Recent News MORE DATE TITLE 11/12/21 Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy 11/10/21 G1 Therapeutics to Participate in Two Upcoming Conferences 11/3/21 G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights 11/1/21 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Recent Events MORE DATE TITLE 12/1/21 at 12:35 PM EST 4th Annual Evercore ISI HealthCONx Conference Listen to webcast 11/17/21 at 8:00 AM EST Stifel 2021 Virtual Healthcare Conference Listen to webcast 11/3/21 at 8:30 AM EDT G1 Therapeutics 3Q 2021 Financial Results Click here for Webcast 9/13/21 at 7:00 AM EDT H.C. Wainwright 23rd Annual Global Investment Conference Listen to Webcast Tools Investor Relations Overview Press Releases Events & Presentations Stock Financials Resources Contact Us Our Company Our Science Patients Careers Investors News Medical Professionals Contact Home © 2019 G1 Therapeutics, Inc. All rights reserved. Website Design: Hane Chow, Inc. LinkedIn Twitter Privacy Policy Cookie Policy Terms of Use